Fig. 2: Clinical outcomes by ctDNA status during- and post-NAT. | Nature Communications

Fig. 2: Clinical outcomes by ctDNA status during- and post-NAT.

From: Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study

Fig. 2

Kaplan–Meier estimates of patients with LAR G/GEJ adenocarcinoma representing (A) RFS & (B) OS stratified by ctDNA status during NAT. C RFS & (D) OS stratified by ctDNA status post-NAT. HRs and 95% CIs were calculated using the Cox proportional hazard model; P-values were calculated using the two-sided log-rank test. Forest plot depicting multivariate analysis for RFS (E) and OS (F) in patients with LAR G/GEJ adenocarcinoma post-NAT. P = 0.000467 (E), P = 0.000735 (F). Various prognostic factors and their association with RFS/OS, as indicated by HR, were analyzed across the cohort using the two-sided Wald chi-squared test. The unadjusted HRs (squares) and 95% CIs (horizontal lines) are shown for each prognostic factor; the vertical dotted line represents the null hypothesis (E, F). ctDNA circulating tumor DNA, Cl Confidence interval, GEJ gastroesophageal junction, HR Hazard ratio, NAT neoadjuvant therapy, NR not reached, RFS Recurrence-free survival, OS Overall survival.

Back to article page